Stock That Is Worth Exploring Now: Atyr Pharma Inc (NASDAQ: ATYR)

Atyr Pharma Inc (NASDAQ:ATYR) does about 453.73K shares in volume on a normal day but saw 5667543 shares change hands in the recent trading day. The company now has a market cap of 169.79M USD. Its current market price is $2.24, marking an increase of 0.45% compared to the previous close of $2.23. The 52 week high reached by this stock is $2.50 whilst the lowest price level in 52 weeks is $1.08.

Atyr Pharma Inc (ATYR) has a 20-day trading average at $1.87 and the current price is -10.40% off the 52-week high compared with 107.39% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.87 and its 200-day simple moving average is $1.77. If we look at the stock’s price movements over the week, volatility stands at 6.77%, which decreases to 4.89% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 74.73 to suggest the stock is overbought.

The consensus objective for the share price is $21.29, suggesting that the stock has a potential upside of 89.48% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on October 04, 2024 when Wells Fargo initiated the stock to “Overweight” and issued a price target of $17.

The current price level is 19.50%, 19.99%, and 26.22% away from its SMA20, SMA50, and SMA200 respectively, with the ATYR price moving below the 50-day SMA on current market day. Atyr Pharma Inc (ATYR) stock is up 18.52% over the week and 17.89% over the past month. Its price is 58.87% year-to-date and 61.15% over the past year.

To reach the target analysts have set, the stock logically needs to grow 89.48 percent from here.

Outstanding shares total 75.80M with insiders holding 2.39% of the shares and institutional holders owning 63.64% of the company’s common stock. The company has a return on investment of -61.41% and return on equity of -61.64%. The beta has a value of 1.20. Price to book ratio is 2.08 and price to sales ratio is 287.78.